VENUSREM vs WINDLAS: Stock Comparison
VENUSREM is the larger company by market capitalisation. VENUSREM shows a lower P/E, a higher ROE and faster revenue growth, while WINDLAS BIOTECH shows a higher dividend yield. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.
Metric snapshot
VENUSREM leads 11; WINDLAS leads 2 of 13
Interactive comparison
Compare the numbers that shape the decision
Every row uses its own scale. Switch lenses to compare like with like.
Valuation lens
What price are you paying?
✓ marks the usual favourable reading; it is not a recommendation.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Profile
| Metric | VENUSREM | WINDLAS |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Pharmaceuticals | Pharmaceuticals |
Price
| Metric | VENUSREM | WINDLAS |
|---|---|---|
| Live Price | ₹1,796.7 | ₹991.6 |
| Day Change | 0.03% | -2.97% |
| Volume | 1.17 L | 1.23 L |
| 52-Week High | ₹1,880 | ₹1,181.9 |
| 52-Week Low | ₹432.1 | ₹697.4 |
| Distance from 52W High | -4.43% | -16.1% |
Valuation
| Metric | VENUSREM | WINDLAS |
|---|---|---|
| Market Cap | ₹2,233 Cr | ₹2,063 Cr |
| P/E Ratio | 19.22x | 43.2x |
| P/B Ratio | 3.36x | 3.63x |
| EPS | ₹19.1 | ₹8.55 |
| Book Value | ₹496.56 | ₹281.47 |
| Dividend Yield | 0.56% | 0.62% |
Growth
| Metric | VENUSREM | WINDLAS |
|---|---|---|
| Revenue Growth (TTM YoY) | 33% | 17.7% |
| EPS Growth (TTM YoY) | 126.4% | -2.6% |
| Qtr Sales Growth | -0.03% | 4.03% |
| Qtr Profit Growth | 11.14% | 10.4% |
Profitability & Leverage
| Metric | VENUSREM | WINDLAS |
|---|---|---|
| ROE | 15.49% | 11.44% |
| ROCE | 16.2% | 11.49% |
| Net Margin | 13.35% | 7.35% |
| Operating Margin | 17.56% | 10.15% |
| Debt to Equity | 0x | 0.05x |
Shareholding
As of Jun 2026 • change vs previous quarter| Metric | VENUSREM | WINDLAS |
|---|---|---|
| Promoter Holding | 41.76% | 63.31%▲ 1.41 pp |
| FII Holding | 2.92%▲ 0.12 pp | 2.04%▲ 1.44 pp |
| DII Holding | 0.89%▼ 0.31 pp | 9.84%▼ 1.97 pp |
| Public Holding | 54.43%▲ 0.19 pp | 24.8%▼ 0.9 pp |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: VENUSREM and WINDLAS BIOTECH.
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.